$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000153217616000045 Filed on February 11, 2016

Income Statement

Concept	2015	2014 Q4	2014 Q3
Revenue	$4.104B	$802.3M	$725.8M
YoY Change	45.55%	31.44%	21.57%
Cost Of Revenue	$241.7M	$59.50M	$33.66M
YoY Change	87.32%	23.7%	19.12%
Gross Profit	$3.862B	$742.9M	$692.1M
YoY Change	43.54%	32.12%	21.69%
Gross Profit Margin	94.11%	92.59%	95.36%
Selling, General & Admin	$838.5M	$175.3M	$144.0M
YoY Change	61.48%	113.53%	47.53%
% of Gross Profit	21.71%	23.6%	20.81%
Research & Development	$1.621B	$351.7M	$337.7M
YoY Change	27.47%	31.18%	50.74%
% of Gross Profit	41.96%	47.34%	48.8%
Depreciation & Amortization	$74.91M	$14.10M	$14.10M
YoY Change	42.18%	24.78%	30.56%
% of Gross Profit	1.94%	1.9%	2.04%
Operating Expenses	$2.459B	$175.3M	$481.7M
YoY Change	37.33%	-49.94%	49.77%
Operating Profit	$1.252B	$215.8M	$188.5M
YoY Change	51.95%	1.75%	-20.41%
Interest Expense	$14.24M	-$6.400M	$9.232M
YoY Change	-61.89%	-45.3%	-21.34%
% of Operating Profit	1.14%	-2.97%	4.9%
Other Income/Expense, Net	-$26.82M	$3.000M	-$6.641M
YoY Change	-57.22%	-230.43%	-40.27%
Pretax Income	$1.225B	$189.7M	$181.8M
YoY Change	60.94%	-4.28%	-19.43%
Income Tax	$589.0M	$99.63M	$98.45M
% Of Pretax Income	48.08%	52.51%	54.14%
Net Earnings	$636.1M	$90.10M	$83.38M
YoY Change	88.11%	-6.93%	-41.0%
Net Earnings / Revenue	15.5%	11.23%	11.49%
Basic Earnings Per Share	$6.17	$0.89	$0.83
Diluted Earnings Per Share	$5.52	$0.78	$0.73
COMMON SHARES
Basic Shares Outstanding	103.1M shares		100.8M shares
Diluted Shares Outstanding	115.2M shares		117.4M shares

Balance Sheet

Concept	2015	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.045B	$900.0M	$1.042B
YoY Change	16.11%	29.68%	134.16%
Cash & Equivalents	$809.0M	$648.7M	$646.6M
Short-Term Investments	$236.0M	$252.0M	$396.0M
Other Short-Term Assets	$200.0M	$159.0M	$139.0M
YoY Change	25.79%	78.65%	-3.47%
Inventory	$202.0M	$128.9M	$120.3M
Prepaid Expenses
Receivables	$1.468B	$739.4M	$673.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.915B	$2.085B	$2.201B
YoY Change	36.79%	16.02%	34.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.594B	$974.3M	$819.0M
YoY Change	63.66%	84.88%	80.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$632.0M	$460.0M	$453.0M
YoY Change	37.39%	17.95%	37.27%
Other Assets	$468.0M	$3.034M	$3.416M
YoY Change	72.06%	-43.04%	-22.52%
Total Long-Term Assets	$2.694B	$1.753B	$1.539B
YoY Change	57.82%	51.89%	52.93%
TOTAL ASSETS
Total Short-Term Assets	$2.915B	$2.085B	$2.201B
Total Long-Term Assets	$2.694B	$1.753B	$1.539B
Total Assets	$5.609B	$3.838B	$3.739B
YoY Change	46.14%	30.05%	41.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$141.0M	$100.0M	$47.00M
YoY Change	41.0%	61.29%	51.61%
Accrued Expenses	$503.0M	$384.0M	$291.0M
YoY Change	30.99%	103.17%	54.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$811.0M	$654.7M	$410.2M
YoY Change	23.82%	119.07%	52.65%
LONG-TERM LIABILITIES
Long-Term Debt	$363.0M	$458.0M	$564.0M
YoY Change	-20.74%	-9.31%	17.26%
Other Long-Term Liabilities	$780.0M	$39.80M	$23.75M
YoY Change	345.71%	251.29%	124.6%
Total Long-Term Liabilities	$1.143B	$39.80M	$23.75M
YoY Change	80.57%	251.29%	124.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$811.0M	$654.7M	$410.2M
Total Long-Term Liabilities	$1.143B	$39.80M	$23.75M
Total Liabilities	$1.954B	$1.287B	$1.188B
YoY Change	51.83%	28.88%	24.98%
SHAREHOLDERS EQUITY
Retained Earnings		$216.6M	$145.2M
YoY Change		-333.72%	-176.63%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$169.5M	$43.85M
YoY Change
Treasury Stock Shares		2.018M shares	521.9K shares
Shareholders Equity	$3.655B	$2.550B	$2.552B
YoY Change
Total Liabilities & Shareholders Equity	$5.609B	$3.838B	$3.739B
YoY Change	46.14%	30.05%	41.62%

Cashflow Statement

Concept	2015	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	$636.1M	$90.10M	$83.38M
YoY Change	88.11%	-6.93%	-41.0%
Depreciation, Depletion And Amortization	$74.91M	$14.10M	$14.10M
YoY Change	42.18%	24.78%	30.56%
Cash From Operating Activities	$1.331B	$198.1M	$164.4M
YoY Change	76.86%	-28.41%	77.73%
INVESTING ACTIVITIES
Capital Expenditures	-$677.9M	-$117.5M	-$79.80M
YoY Change	103.57%	70.29%	152.53%
Acquisitions
YoY Change
Other Investing Activities	-$229.7M	$174.2M	-$43.30M
YoY Change	161.62%	-525.92%	-76.31%
Cash From Investing Activities	-$907.6M	$56.60M	-$123.0M
YoY Change	115.7%	-151.45%	-42.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$206.4M
YoY Change	63.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$262.8M	-252.6M	5.200M
YoY Change	20.25%	-339.43%	44.44%
NET CHANGE
Cash From Operating Activities	$1.331B	198.1M	164.4M
Cash From Investing Activities	-$907.6M	56.60M	-123.0M
Cash From Financing Activities	-$262.8M	-252.6M	5.200M
Net Change In Cash	$160.4M	2.100M	46.60M
YoY Change	41.79%	-99.23%	-139.39%
FREE CASH FLOW
Cash From Operating Activities	$1.331B	$198.1M	$164.4M
Capital Expenditures	-$677.9M	-$117.5M	-$79.80M
Free Cash Flow	$2.009B	$315.6M	$244.2M
YoY Change	85.06%	-8.71%	96.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	50626000000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2013Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	16100000	USD
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2015Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	50700000	USD
CY2014Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	41555000	USD
CY2015Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	88297000	USD
CY2014Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	133085000	USD
CY2015Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	195986000	USD
CY2015Q4	regn	Annualrentescalationpercentage Annualrentescalationpercentage	0.025
CY2014	regn	Branded Prescription Drug Fee BrandedPrescriptionDrugFee	40600000	USD
CY2013	regn	Costofmanufacturing Costofmanufacturing	37307000	USD
CY2014	regn	Costofmanufacturing Costofmanufacturing	75988000	USD
CY2015	regn	Costofmanufacturing Costofmanufacturing	151007000	USD
CY2014	regn	Debt Conversion DebtConversion	230600000	USD
CY2013	regn	Decreaseintotalcashfromfinancing Decreaseintotalcashfromfinancing	4900000	USD
CY2014	regn	Decreaseintotalcashfromfinancing Decreaseintotalcashfromfinancing	9300000	USD
CY2014Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	58098000	USD
CY2015Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	51914000	USD
CY2014Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	72430000	USD
CY2015Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	82015000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	15927000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	101573000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	62819000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	582664000	USD
CY2014Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	12908000	USD
CY2015Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	7725000	USD
CY2014Q4	regn	Deferredtaxassetreclassification Deferredtaxassetreclassification	46200000	USD
CY2014Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	312292000	USD
CY2015Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	364708000	USD
CY2014Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	310938000	USD
CY2015Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	362919000	USD
CY2013	regn	Increaseintotalcashfromoperating Increaseintotalcashfromoperating	4900000	USD
CY2014	regn	Increaseintotalcashfromoperating Increaseintotalcashfromoperating	9300000	USD
CY2013	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	433000	shares
CY2014	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	425000	shares
CY2014Q4	regn	Reductionin Apic ReductioninAPIC	14200000	USD
CY2014Q4	regn	Reductionindeferredrevenue Reductionindeferredrevenue	41000000	USD
CY2015	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	477000	shares
CY2013	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16200000	USD
CY2014	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	14500000	USD
CY2015	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	9700000	USD
CY2014	regn	Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million	100000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million	500000000	USD
CY2014Q4	regn	Limitpricepershareforwarrantholderstocloseouthedgeposition Limitpricepershareforwarrantholderstocloseouthedgeposition	397.75
CY2015Q4	regn	Limitpricepershareforwarrantholderstocloseouthedgeposition Limitpricepershareforwarrantholderstocloseouthedgeposition	535.00
CY2014	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	148496000	USD
CY2015	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	23317000	USD
CY2014Q4	regn	Maximumreductionofwarrantsheldbywarrantholder Maximumreductionofwarrantsheldbywarrantholder	493229	shares
CY2015Q4	regn	Maximumreductionofwarrantsheldbywarrantholder Maximumreductionofwarrantsheldbywarrantholder	476376	shares
CY2015	regn	Numberofdemandrightstorequirethe Companytoconductregisteredunderwrittenpublicoffering NumberofdemandrightstorequiretheCompanytoconductregisteredunderwrittenpublicoffering	3
CY2013	regn	Other Collaboration Revenue OtherCollaborationRevenue	220289000	USD
CY2014	regn	Other Collaboration Revenue OtherCollaborationRevenue	495555000	USD
CY2015	regn	Other Collaboration Revenue OtherCollaborationRevenue	580488000	USD
CY2015Q4	regn	Percentage Of Prompt Pay Discount Company Accrues PercentageOfPromptPayDiscountCompanyAccrues	1
CY2014	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2014Q4	regn	Reductioninaccountsreceivable Reductioninaccountsreceivable	41000000	USD
CY2014Q4	regn	Reductioninincometaxassetsnet Reductioninincometaxassetsnet	14200000	USD
CY2013	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	11500000	USD
CY2014	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	13600000	USD
CY2015	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	15500000	USD
CY2014Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	125483000	USD
CY2015Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	162152000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	483489000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	644112000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	99508000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	140962000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	739379000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1152489000	USD
CY2014Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	111510000	USD
CY2015Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	153152000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	253984000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	331096000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	52251000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8572000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2450782000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3099526000	USD
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	211909000	USD
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	439278000	USD
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	405317000	USD
CY2013	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	195087000	USD
CY2014	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2015	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	160538000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	691869000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	819657000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-294552000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-449456000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	217080000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326815000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	464022000	USD
CY2013	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	174858000	USD
CY2014	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	414309000	USD
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	694724000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014Q4	us-gaap	Assets Assets	3837672000	USD
CY2015Q4	us-gaap	Assets Assets	5609132000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2084759000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	2915095000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	711915000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	868282000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	81989000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14622000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1551000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2769000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	631477000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	856429000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	92000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	1551000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	2769000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	426941000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	755080000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1551000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2677000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	426941000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	731331000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	23749000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1128000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	360208000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	600695000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	251761000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	236121000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	613097000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	836816000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1000000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1200000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2014Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	398981000	USD
CY2015Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	760517000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	472367000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	31176000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	34234000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	33442000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	32667000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	31913000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	308935000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230276000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	809102000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	305332000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	113111000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	160383000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	413716000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	391565000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	592377000	USD
CY2014	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.70
CY2015	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.68
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	472231000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	579834000	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	146773000	USD
CY2015Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	118048000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	129030000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	241702000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	1361695000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	1995638000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	2851812000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	196527000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	437038000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	686561000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	433000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2879000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4004000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	220449000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	468635000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	719133000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	23489000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28718000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28568000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	53504000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-9000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-62932000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-119849000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1485000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-6475000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	62195000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-45526000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-130092000	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32016000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21294000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	74025000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	153487000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	135249000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	664679000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8700000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	18891000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3768000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	60223000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	51766000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	347791000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	483239000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	315416000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	461945000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	315416000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	461945000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	347432000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	483239000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	150000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	140000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21922000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26580000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	8078000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8539000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	216640000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	349508000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	19331000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	47520000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	359000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	28186000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	3280000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	252000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3578000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12455000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5559000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5700000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	13100000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	15400000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41204000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52686000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74909000	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.23
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.69
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.96
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.36
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.74
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.04
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.17
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.72
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.98
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.69
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.34
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.406
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.556
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.481
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.029
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.028
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.020
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.032
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.049
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.158
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.122
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.018
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.049
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.051
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.016
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	92778000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	133223000	USD
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	211909000	USD
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	439278000	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	405317000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1200000	USD
CY2014Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2015Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	91400000	USD
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	58655000	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	81381000	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-33469000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-18861000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	696382000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	761235000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1225097000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	282644000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423109000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	589041000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	34000000	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1057000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	59847000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	276092000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	136684000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	161182000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	303657000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	245472000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34927000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	491421000	USD
CY2013	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-62195000	USD
CY2014	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	53276000	USD
CY2015	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	121623000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-41496000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8403000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	608892000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47956000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56947000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	111825000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7571000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	45327000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	79476000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2707000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2936000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2246000	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10233000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9440000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9446000	shares
CY2013	us-gaap	Interest Expense InterestExpense	46437000	USD
CY2014	us-gaap	Interest Expense InterestExpense	37372000	USD
CY2015	us-gaap	Interest Expense InterestExpense	14241000	USD
CY2013	us-gaap	Interest Paid Net InterestPaidNet	23197000	USD
CY2014	us-gaap	Interest Paid Net InterestPaidNet	20348000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	10582000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10768000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11197000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	128861000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	238578000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10923000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	59151000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	73519000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	132068000	USD
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	9100000	USD
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	6000000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	10600000	USD
CY2014Q4	us-gaap	Land Land	2768000	USD
CY2015Q4	us-gaap	Land Land	77826000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	42600000	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	95226000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1287421000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	1954295000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3837672000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5609132000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	654660000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	811162000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	28506000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	31941000	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	74889000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	251761000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	27100000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	24900000	USD
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	236121000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	460154000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	632162000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72191000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-218547000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-262796000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-355455000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420777000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-907601000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	588596000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	752435000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1330780000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	413738000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	68305000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	96351000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	83375000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	90095000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	338126000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	76021000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	194643000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	210398000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	154994000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	636056000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46668000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-62684000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26819000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	743050000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	823919000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	1251916000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	112853000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	15488000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	11375000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	11740000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	11747000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	11757000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	50746000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	9875000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14312000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	15202000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	116563000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	85644000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3034000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5810000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53439000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-43679000	USD
CY2014Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	33651000	USD
CY2015Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	36162000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97146000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13563000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39801000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115535000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-46751000	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-44102000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-33701000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-231000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8157000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6283000	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	294552000	USD
CY2015	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	573487000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	195087000	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	160537000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	577278000	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	564188000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	557105000	USD
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	156323000	USD
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	333006000	USD
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	677933000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79046000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	163501000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57393000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126045000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	206358000	USD
CY2013	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-2024000	USD
CY2014	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-1095000	USD
CY2015	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	26020000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	378146000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	476417000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	327437000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1228293000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1925216000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974309000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1594120000	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	220639000	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	166467000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859947000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1271353000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1620577000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	216644000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	852700000	USD
CY2013	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	430111000	USD
CY2014	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	541299000	USD
CY2015	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	758873000	USD
CY2013	us-gaap	Revenues Revenues	2104745000	USD
CY2014Q1	us-gaap	Revenues Revenues	625740000	USD
CY2014Q2	us-gaap	Revenues Revenues	665700000	USD
CY2014Q3	us-gaap	Revenues Revenues	725788000	USD
CY2014Q4	us-gaap	Revenues Revenues	802329000	USD
CY2014	us-gaap	Revenues Revenues	2819557000	USD
CY2015Q1	us-gaap	Revenues Revenues	869612000	USD
CY2015Q2	us-gaap	Revenues Revenues	998617000	USD
CY2015Q3	us-gaap	Revenues Revenues	1137422000	USD
CY2015Q4	us-gaap	Revenues Revenues	1098077000	USD
CY2015	us-gaap	Revenues Revenues	4103728000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1425839000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1750762000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2689478000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	346393000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	519267000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	838526000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	215377000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	321750000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	459049000	USD
CY2014	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2017732	shares
CY2015	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1625113	shares
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	691356000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	818360000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	5718000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	13125000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	15382000	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	1964716000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2550251000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3654837000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2017732	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3642820	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	169530000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54762000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125897000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215462000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1256618000	USD
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11274000	USD
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	306069000	USD
CY2014	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26627000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	57615000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	116572000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	572000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3014000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7620000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	27538000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	59909000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	1200000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	8305000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	6464000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-952000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	23500000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	51200000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	102100000	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	18826000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55249000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	89875000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	111855000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	193190000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	84100000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	111675000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	162722000	USD
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13373000	shares
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12801000	shares
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12169000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111290000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113413000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115230000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97917000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100612000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103061000	shares
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. A large portion of the Company's cash is held by a few major financial institutions. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are significant. Accounts receivable from product sales of EYLEA and ARCALYST are due from several distributors and specialty pharmacies, who are the Company's customers. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014, one individual customer accounted for </font><font style="font-family:inherit;font-size:10pt;">68%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. As of December 31, 2015 and 2014, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves against trade accounts receivable. In addition, during the years ended December 31, 2015, 2014, and 2013, the Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t recognize any charges for write-offs of trade accounts receivable. </font></div></div>
CY2015	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to several distributors and specialty pharmacies. The Company sells ARCALYST in the United States to two specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services ("PHS"), and other institutions (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Pay Discounts: </font><font style="font-family:inherit;font-size:10pt;"> No prompt pay discounts are currently offered to the Company's customers on sales of EYLEA. In connection with sales of ARCALYST, the Company offers discounts to its customers for prompt payments. The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount. Therefore, the Company accrues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the prompt pay discount that is based on the gross amount of each ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">invoice, at the time of sale.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include provisions related to product sales, such as rebates, chargebacks, and distribution-related fees; periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements; periods over which certain clinical trial costs are recognized; fair value of stock options; inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value; capitalization of inventory costs associated with the Company's products prior to regulatory approval; deferred tax asset valuation allowances; and the assessment of uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer HealthCare:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of antibodies, which is provided by Sanofi, and include an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer HealthCare collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer HealthCare, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of development expenses incurred by Bayer HealthCare and Sanofi, including the Company's share of Bayer HealthCare and Sanofi estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent period are adjusted, if necessary, in the subsequent period to reflect actual amounts.</font></div></div>

Files In Submission

Name	View Source	Status
0001532176-16-000045-index-headers.html	Edgar Link	pending
0001532176-16-000045-index.html	Edgar Link	pending
0001532176-16-000045.txt	Edgar Link	pending
0001532176-16-000045-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123115x10k.htm	Edgar Link	pending
regn-123115_chartx06558a02.jpg	Edgar Link	pending
regn-20151231.xml	Edgar Link	completed
regn-20151231.xsd	Edgar Link	pending
regn-20151231_cal.xml	Edgar Link	unprocessable
regn-20151231_def.xml	Edgar Link	unprocessable
regn-20151231_lab.xml	Edgar Link	unprocessable
regn-20151231_pre.xml	Edgar Link	unprocessable
regn-ex32x12312015x10k.htm	Edgar Link	pending
regn-ex_10210x12312015x10k.htm	Edgar Link	pending
regn-ex_1025x12312015x10k.htm	Edgar Link	pending
regn-ex_10264x12312015x10k.htm	Edgar Link	pending
regn-ex_1026x12312015x10k.htm	Edgar Link	pending
regn-ex_211x12312015x10k.htm	Edgar Link	pending
regn-ex_231x12312015x10k.htm	Edgar Link	pending
regn-ex_311x12312015x10k.htm	Edgar Link	pending
regn-ex_312x12312015x10k.htm	Edgar Link	pending
regn-ex_32x12312015x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2015 Form 10-K Financial Statement

#000153217616000045 Filed on February 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2015 Form 10-K Financial Statement

#000153217616000045 Filed on February 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn